ArticleFrontiers in nutrition2022
Article in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Anti-PD-L1 improves barrier function and reduces CD103Biomedical journal · 2025Article
- Lactobacillus delbrueckii Alleviate Oxidative Stress and Intestinal Injuries by Activating TLR2 and TLR4 Expressions in IPEC-J2 Cells.Probiotics and antimicrobial proteins · 2025Article
- Article
- Blood cell perturbation responses mediate the causal relationship between the gut microbiota and asthma: a bidirectional Mendelian randomization study.BMC medical genomics · 2025Article
- The gut microbiota modulates airway inflammation in allergic asthma through the gut-lung axis related immune modulation: A review.Biomolecules & biomedicine · 2025Review
- Impact of Early-Life Microbiota on Immune System Development and Allergic Disorders.Biomedicines · 2025Review
- Mogroside V protects lipopolysaccharides-induced lung inflammation chicken via suppressing inflammation mediated by the Th17 through the gut-lung axis.Journal of animal science · 2025Article
- Advances in gut-lung axis research: clinical perspectives on pneumonia prevention and treatment.Frontiers in immunology · 2025Review
- Lung microbiome: new insights into the pathogenesis of respiratory diseases.Signal transduction and targeted therapy · 2024Review
- Characteristics of lower respiratory tract pathogens in critically ill patients with heatstroke: a retrospective multi-center study.Frontiers in cellular and infection microbiology · 2024Article
- The panda-derived Lactiplantibacillus plantarum BSG201683 improves LPS-induced intestinal inflammation and epithelial barrier disruption in vitro.BMC microbiology · 2023Article
- Review
- Winds of change a tale of: asthma and microbiome.Frontiers in microbiology · 2023Review
- Extensively Hydrolyzed Hypoallergenic Infant Formula with Retained T Cell Reactivity.Nutrients · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asthma is a chronic disease, which is harmful to the health of the body and the quality of life. Supplementation of Methods: A mouse ovalbumin (OVA)-induced model was constructed. OVA mice were supplemented with Results: Compared with Control mice, OVA mice exhibited malignant conditions, such as intestinal leakage and lung edema. After supplementation with Conclusion: The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.